EBR Systems, Inc. reports strong commercial momentum in Q4 2025 with doubled case volumes compared to Q3 2025.
The WiSE® System was successfully implanted in 18 commercial patients during the quarter, reaching a total of 30 implants for the combined pilot phase and Limited Market Release.
Preliminary unaudited year-end results estimate revenue in the range of US$870K to US$935K for Q4 2025 and US$1,552K to US$1,617K for total 2025 revenue.
Commercial Momentum
Case volumes doubled in Q4 2025, reflecting growing physician experience.
System Implantation
18 commercial patients received successful WiSE® System implants in the quarter.
Revenue Expectation
Preliminary unaudited results project Q4 2025 revenue between US$870K and US$935K.
Market Release Progress
9 new purchase agreements were signed in Q4, supporting WiSE adoption.
Clinical Studies
WiSE-UP post-approval study and TLC-AU feasibility study began in Q4 2025.
- The company's limited market release saw progress with new purchase agreements and physician training.
- Important clinical initiatives, like the WiSE-UP post-approval study, show promising advancements in CRT for heart failure patients.
EBR Systems continues its disciplined execution, focusing on building evidence for broader WiSE System adoption and enhancing cardiovascular care.